Clinical Trials on Refractory Primary Amyloidosis

Total 62134 results

M.D. Anderson Cancer Center
Takeda; Janssen Pharmaceuticals

Active, not recruiting

Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis

Recurrent Primary Amyloidosis | Refractory Primary Amyloidosis | Newly Diagnosed Primary Amyloidosis

United States
Millennium Pharmaceuticals, Inc.

Terminated

Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

Relapsed or Refractory Systemic Light Chain Amyloidosis

United States, Canada, Spain, Israel, France, Australia, Denmark, Germany, Korea, Republic of, Greece, Netherlands, Brazil, Czechia, Italy, United Kingdom
Regeneron Pharmaceuticals

Not yet recruiting

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis) (LINKER-AL2)

Relapsed/Refractory Systemic Light Chain Amyloidosis
Weill Medical College of Cornell University
Janssen Scientific Affairs, LLC

Recruiting

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

AL Amyloidosis | Amyloid | Refractory AL Amyloidosis

United States
Chulalongkorn University

Unknown

Efficacy of Methylene Blue Mediated Photodynamic Therapy for Primary Localized Cutaneous Amyloidosis Treatment in Asians

Lichen Amyloidosis

Thailand
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

Nausea | Constipation | Diarrhea | Purpura | Lymphadenopathy | Gastrointestinal Hemorrhage | Hepatomegaly | Primary Systemic Amyloidosis | Amorphous, Eosinophilic, and Acellular Deposit | Early Satiety | Macroglossia | Recurrent Primary Amyloidosis | Refractory Primary Amyloidosis

United States
PETHEMA Foundation

Completed

Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed (LENDEXAL)

Primary Systemic Amyloidosis

Spain
National Cancer Institute (NCI)

Terminated

Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis

Primary Systemic Amyloidosis

United States
University Hospital, Limoges
Ministry of Health, France

Completed

Intensive Versus Conventional Treatment in Patients With Primary Amyloidosis

Primary Systemic Amyloidosis (AL)

France
National Cancer Institute (NCI)

Completed

Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis

Primary Systemic Amyloidosis | Light Chain Deposition Disease

United States
Mayo Clinic

Completed

Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis

Primary Systemic Amyloidosis

United States
The Cleveland Clinic

Completed

Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis

Primary Systemic Amyloidosis
Medical College of Wisconsin
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis Trial (DUAL)

Primary Systemic Amyloidosis

United States
Barbara Ann Karmanos Cancer Institute
Bristol-Myers Squibb; National Cancer Institute (NCI); Multiple Myeloma Research...

Active, not recruiting

Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis

Recurrent Primary Amyloidosis

United States
University of Tennessee
FDA Office of Orphan Products Development

Completed

Radioimmunoimaging of AL Amyloidosis

Primary Amyloidosis

United States
Alnylam Pharmaceuticals

Completed

DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis

Familial Amyloidotic Cardiomyopathy (FAC)

United States, France, Spain, United Kingdom, Belgium, Brazil
Alnylam Pharmaceuticals

Completed

ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

Amyloid Neuropathies | Amyloid Neuropathies, Familial | Amyloidosis, Hereditary | Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) | Amyloidosis, Hereditary, Transthyretin-Related | Familial Transthyretin Cardiac Amyloidosis

United States, France, Italy, Spain, Canada, Germany, Belgium, Sweden, United Kingdom
Sanofi

Recruiting

A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)

Relapsed/Refractory Multiple Myeloma | Amyloid Light-chain Amyloidosis

Italy, Australia, Belgium, Hungary, Spain, United Kingdom, Czechia
Alnylam Pharmaceuticals

Completed

The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant

ATTR Amyloidosis | Transthyretin (TTR)-Mediated Amyloidosis | Familial Amyloidotic Polyneuropathy (FAP) | Familial Amyloid Neuropathies

France, Germany, Portugal, United Kingdom, Sweden, Spain
Chulalongkorn University
Ratchadapiseksompotch Fund

Unknown

Efficacy of 308-nm Excimer Laser for Primary Localized Cutaneous Amyloidosis Treatment in Asians

Lichen Amyloidosis

Thailand
Prothena Biosciences Ltd.

Terminated

The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis (VITAL)

Primary Systemic (AL) Amyloidosis

United States, Spain, Israel, Canada, Poland, Netherlands, France, Germany, United Kingdom, Belgium, Denmark, Greece, Australia, Austria, Italy
IRCCS Policlinico S. Matteo

Terminated

Epigallocatechingallate (EGCG) in Cardiac AL Amyloidosis (EpiCardiAL)

Primary Amyloidosis of Light Chain Type

Italy
IRCCS Policlinico S. Matteo

Completed

Pomalidomide and Dexamethasone (PDex) in AL Amyloidosis

Primary Amyloidosis of Light Chain Type

Italy
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Terminated

First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD

Primary Systemic Amyloidosis | Light Chain Deposition Disease

United States, Canada
Selayang Hospital

Completed

A Randomised, Open-Label, Cross Over Group, Single-Centre Controlled Study To Evaluate The Clinical Performance Of Medium Cut-Off Membrane Dialyser Compared With High Flux Dialyser Among Patients With Chronic Haemodialysis (HD-1)

Quality of Life | Dialysis Amyloidosis | Hemodialysis-Associated Amyloidosis

Malaysia
Prothena Biosciences Ltd.

Completed

Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis

Primary Amyloidosis

United States
Heidelberg University
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH

Completed

A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) Amyloidosis (LEOMEX)

Primary Amyloidosis

Germany
Millennium Pharmaceuticals, Inc.

Completed

Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis

Light-Chain Amyloidosis

United States, Canada, France, Germany, Italy
Boston University
Corino Therapeutics, Inc.

Completed

Short-term Effects of TOLCAPONE on Transthyretin Stability in Subjects With Leptomeningeal TTR Amyloidosis (ATTR)

Transthyretin Amyloidosis | Amyloidosis, Leptomeningeal, Transthyretin-Related

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease

Primary Systemic Amyloidosis | Light Chain Deposition Disease

United States
IRCCS Policlinico S. Matteo

Withdrawn

High Cut-off Hemodialysis in Patients With Advanced Cardiac AL Amyloidosis and End Stage Renal Disease (DIACAL)

Primary Amyloidosis of Light Chain Type

Italy
Criterium, Inc.
Amgen

Completed

A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis

Amyloidosis | Systemic Light Chain Amyloidosis

United States
Steen Hvitfeldt Poulsen

Recruiting

Prevalence of wtATTR-CM After Carpal Tunnel Release Surgery (CACTuS2)

Transthyretin Amyloidosis | Transthyretin Cardiac Amyloidosis | Wild-Type Transthyretin-Related (ATTR)Amyloidosis

Denmark
Stanford University

Completed

Autologous Stem Cell Rescue for Primary Amyloidosis

Amyloidosis | Blood and Marrow Transplant (BMT)

United States
IRCCS Policlinico S. Matteo

Recruiting

The Italian Transthyretin Amyloidosis Web-Network (ITA-WebNet)

ATTR Amyloidosis

Italy
University Hospital Center of Martinique

Terminated

Mitochondrial Function in Transthyretin Amyloidosis (MIT-Amylose)

Cardiac Amyloidosis

Martinique
Stanford University

Withdrawn

Mixed Chimeric Transplantation for Primary Amyloidosis

Amyloidosis
Tufts Medical Center

Completed

Minimal Residual Disease as a Possible Predictive Factor for Relapse in Patients With AL Amyloidosis

Amyloidosis | Primary Amyloidosis

United States
Kaneka Medical America LLC

Recruiting

Post Approval Study of Lixelle for the Treament of Dialysis-Related Amyloidosis

Dialysis Amyloidosis

United States
Mayo Clinic

Completed

Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic Amyloidosis

Amyloidosis

United States
Peking Union Medical College Hospital

Recruiting

Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14)

Light Chain (AL) Amyloidosis | Venetoclax | CCND1 Translocation

China
Tufts Medical Center
Sanofi

Withdrawn

Isatuximab and Bendamustine in Systemic Light Chain Amyloidosis

Amyloidosis | Light Chain (AL) Amyloidosis
Austin Neuromuscular Center
Alnylam Pharmaceuticals

Recruiting

Spectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amyloidosis and Response to Patisiran Therapy

Polyneuropathies | Transthyretin Amyloidosis | Wild-Type Transthyretin-Related (ATTR)Amyloidosis | Wild-Type Transthyretin Cardiac Amyloidosis | Wild Type ATTR Amyloidosis

United States
University of Tennessee Graduate School of Medicine
Attralus, Inc.

Recruiting

A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis

Systemic Amyloidosis

United States
Samsung Medical Center

Recruiting

Physiologic Assessment of Microvascular Function in Patients With Cardiac Amyloidosis

Cardiac Amyloidosis

Korea, Republic of
Mayo Clinic

Enrolling by invitation

Artificial Intelligence Enhanced ECG to Detect Cardiac Amyloidosis

Cardiac Amyloidosis

United States
University of Tennessee Graduate School of Medicine

Completed

124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis

Systemic Amyloidosis

United States
University Hospital, Toulouse

Terminated

Assessment of Cardiac Fixation During PET Using a New Drug Within Amyloid Cardiac Injuries. (AMYLCAR)

Cardiac Amyloidosis

France
Stanford University

Completed

PET/MRI Evaluation of Cardiac Amyloid

Cardiac Amyloidosis

United States
Midwest Heart & Vascular Specialists

Recruiting

Amyloidosis Incidence in High-Risk Cardiac Device Patients

AL Amyloidosis | Amyloid | Cardiac Amyloidosis | Amyloidosis Cardiac | Systemic Amyloidosis | ATTR Amyloidosis Wild Type | Infiltrative Cardiomyopathy, Amyloid

United States

Clinical Trials on Refractory Primary Amyloidosis

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations